Medicare Part D Smoothing Program: Impact on Access and Adherence

Author(s):

Kirollos Hanna, PharmD, BCPS, BCOP,Brandon Dyson, PharmD, BCPS

Key Takeaways

The Medicare Part D smoothing program will distribute out-of-pocket costs for BTK inhibitors, potentially enhancing CLL patient adherence.
Improved access to BTK inhibitors is anticipated due to reduced financial barriers for CLL patients under the new program.
Pharmacists are essential in assisting providers and patients to navigate the Medicare Part D changes, ensuring effective treatment management.

The discussion explores how Medicare's Part D smoothing program in 2025 might impact chronic lymphocytic leukemia patients’ access to and adherence to Bruton tyrosine kinase inhibitor therapies and how pharmacists can help navigate this new program. The session concludes with closing remarks.

EP: 1.BTK Inhibitor-Associated Adverse Events

EP: 2.Managing Adverse Events and Supportive Care Measures in CLL Treatment

EP: 3.Impact of Dose Modifications on CLL Treatment

EP: 4.Considerations for Dose Modifications

EP: 5.Economic Impact of Dose Modifications on CLL Management

EP: 6.Factors to Consider When Switching Therapies

Now Viewing

EP: 7.Medicare Part D Smoothing Program: Impact on Access and Adherence

Video content above is prompted by the following:

How might Medicare’s Part D smoothing program in 2025 affect chronic lymphocytic leukemia patients’ access to and adherence to Bruton tyrosine kinase inhibitor therapies, and how can pharmacists assist providers and patients in navigating this new program?
Closing remarks